Landewé, Robert BM
van der Heijde, Désirée https://orcid.org/0000-0002-5781-158X
Dougados, Maxime
Baraliakos, Xenofon
Van den Bosch, Filip E
Gaffney, Karl
Bauer, Lars
Hoepken, Bengt
Davies, Owen R
de Peyrecave, Natasha
Thomas, Karen
Gensler, Lianne
Clinical trials referenced in this document:
Documents that mention this clinical trial
Comparison of established and preliminarily proposed ASAS MRI working group cut-offs for inflammatory MRI lesions in the sacroiliac joints in radiographic and non-radiographic axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2023-003886
OP0103 DOES GENDER, AGE OR SUBPOPULATION INFLUENCE THE MAINTENANCE OF CLINICAL REMISSION IN AXIAL SPONDYLOARTHRITIS FOLLOWING CERTOLIZUMAB PEGOL DOSE REDUCTION?
https://doi.org/10.1136/annrheumdis-2020-eular.2361
POS0229 DISEASE ACTIVITY AND INFLAMMATION FOLLOWING WITHDRAWAL OF CERTOLIZUMAB PEGOL TREATMENT IN AXIAL SPONDYLOARTHRITIS PATIENTS WHO DID NOT EXPERIENCE FLARES DURING THE C-OPTIMISE STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.1547
Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2
https://doi.org/10.1136/rmdopen-2017-000566
FRI0397 EFFICACY AND SAFETY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL: RESULTS FROM THE 48-WEEK RUN-IN PART OF C-OPTIMISE
https://doi.org/10.1136/annrheumdis-2019-eular.3053
POS0679 COMPARISON OF ESTABLISHED AND NEW, PRELIMINARY PROPOSED ASAS CUT-OFFS FOR INFLAMMATORY MRI LESIONS IN THE SACROILIAC JOINTS OF AXIAL SPONDYLOARTHRITIS PATIENTS AND IMPLICATIONS FOR RECRUITMENT IN CLINICAL STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.2509
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction (Results)
https://doi.org/10.1136/annrheumdis-2019-216839
Performance analysis of a deep-learning algorithm to detect the presence of inflammation in MRI of sacroiliac joints in patients with axial spondyloarthritis
https://doi.org/10.1136/ard-2024-225862
POS0341 PERFORMANCE ANALYSIS OF A DEEP LEARNING ALGORITHM TO DETECT POSITIVE SIJ MRI ACCORDING TO THE ASAS DEFINITION IN AXSPA PATIENTS
https://doi.org/10.1136/annrheumdis-2023-eular.2357
Documents that mention this clinical trial
Comparison of established and preliminarily proposed ASAS MRI working group cut-offs for inflammatory MRI lesions in the sacroiliac joints in radiographic and non-radiographic axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2023-003886
OP0103 DOES GENDER, AGE OR SUBPOPULATION INFLUENCE THE MAINTENANCE OF CLINICAL REMISSION IN AXIAL SPONDYLOARTHRITIS FOLLOWING CERTOLIZUMAB PEGOL DOSE REDUCTION?
https://doi.org/10.1136/annrheumdis-2020-eular.2361
POS0229 DISEASE ACTIVITY AND INFLAMMATION FOLLOWING WITHDRAWAL OF CERTOLIZUMAB PEGOL TREATMENT IN AXIAL SPONDYLOARTHRITIS PATIENTS WHO DID NOT EXPERIENCE FLARES DURING THE C-OPTIMISE STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.1547
Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2
https://doi.org/10.1136/rmdopen-2017-000566
FRI0397 EFFICACY AND SAFETY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL: RESULTS FROM THE 48-WEEK RUN-IN PART OF C-OPTIMISE
https://doi.org/10.1136/annrheumdis-2019-eular.3053
POS0679 COMPARISON OF ESTABLISHED AND NEW, PRELIMINARY PROPOSED ASAS CUT-OFFS FOR INFLAMMATORY MRI LESIONS IN THE SACROILIAC JOINTS OF AXIAL SPONDYLOARTHRITIS PATIENTS AND IMPLICATIONS FOR RECRUITMENT IN CLINICAL STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.2509
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction (Results)
https://doi.org/10.1136/annrheumdis-2019-216839
Performance analysis of a deep-learning algorithm to detect the presence of inflammation in MRI of sacroiliac joints in patients with axial spondyloarthritis
https://doi.org/10.1136/ard-2024-225862
POS0341 PERFORMANCE ANALYSIS OF A DEEP LEARNING ALGORITHM TO DETECT POSITIVE SIJ MRI ACCORDING TO THE ASAS DEFINITION IN AXSPA PATIENTS
https://doi.org/10.1136/annrheumdis-2023-eular.2357
Funding for this research was provided by:
UCB Pharma
This article is maintained by: Elsevier
Article Title: Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
Journal Title: Annals of the Rheumatic Diseases
CrossRef DOI link to publisher maintained version: https://doi.org/10.1136/annrheumdis-2019-216839
Content Type: article
Copyright: Copyright © 2020 © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.